Investigational new drugs for allergic rhinitis.

Expert Opin Investig Drugs 2017 Mar;26(3):279-292

a Department of Internal Medicine , University of South Florida Morsani College of Medicine, Division of Allergy and Immunology , Tampa , FL , USA.

Introduction: Allergic rhinitis (AR) is a multifactorial disease characterized by paroxysmal symptoms of sneezing, rhinorrhea, postnasal drip and nasal congestion. For over a century, subcutaneous allergen immunotherapy (SCIT) has been recognized as the most effective therapy to date that may modify the underlying disease course and provide long-term benefits for individuals refractory to pharmacotherapy. However, over the past 25 years, there has been substantial growth in developing alternative therapies to traditional SCIT. Areas covered: This article will review the most current literature focusing on advancements of AR therapies. Novel AR therapies that are currently under investigation include: the addition of omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody (mAb), to SCIT; altering the method of delivery of allergen immunotherapy (AIT) including sublingual (SLIT), epicutaneous (EIT), intralymphatic (ILIT), intranasal (INIT) and oral mucosal immunotherapy (OMIT); use of capsaicin spray; novel H3 and H4 antihistamines; activation of the innate immune system through Toll-like receptor agonists; and the use of chemically altered allergens, allergoids, recombinant allergens and relevant T-cell epitope peptides to improve the efficacy and safety of AIT. Expert opinion: These promising novel therapies may offer more effective and/or safer treatment options for AR patients, and in some instances, induce immunologic tolerance.

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2017.1290079DOI Listing
March 2017
4 Reads

Publication Analysis

Top Keywords

novel therapies
8
allergen immunotherapy
8
allergic rhinitis
8
including sublingual
4
sublingual slit
4
slit epicutaneous
4
ait including
4
immunotherapy ait
4
altering method
4
scit altering
4
delivery allergen
4
method delivery
4
eit intralymphatic
4
oral mucosal
4
mucosal immunotherapy
4
immunotherapy omit
4
init oral
4
intranasal init
4
mab scit
4
intralymphatic ilit
4

Similar Publications